Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy

NCT ID: NCT02434146

Last Updated: 2019-12-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-05-14
• Study Completion Date: 2017-01-25

Brief Summary

This phase I/II trial studies the safety of topical phenylephrine solution and to see how well it works in preventing oral mucosa (mouth sores) in bone marrow transplant patients receiving cyclophosphamide and total body radiation therapy. Topical phenylephrine solution may prevent or lessen the severity of oral mucosa in patients receiving cyclophosphamide and total body radiation prior to undergoing a bone marrow transplant.

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of phenylephrine (topical phenylephrine solution) applied topically to the oral mucosa of bone marrow transplant patients treated with cyclophosphamide plus total body irradiation.

II. To determine the maximum tolerated dose (MTD) and recommended phase II dose of phenylephrine applied topically to the oral mucosa of bone marrow transplant patients treated with cyclophosphamide plus total body irradiation.

III. To evaluate the efficacy of phenylephrine applied topically to the oral mucosa in preventing and/or decreasing severity of oral mucositis in bone marrow transplant patients treated with cyclophosphamide plus total body irradiation.

OUTLINE: This is a phase I, dose-escalation study of topical phenylephrine solution followed by a phase II study.

Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.

After completion of study treatment, patients are followed up weekly for 2 weeks and then at 3 months.

Conditions

Neoplasm; Oral Mucosa; Transplant-Related Disorder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Supportive care (topical phenylephrine solution)

Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.

Group Type: EXPERIMENTAL

Topical Phenylephrine Solution

Intervention Type: DRUG

Given topically via spray

Interventions

Topical Phenylephrine Solution

Given topically via spray

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
• Patients must have no evidence of active infections at the time of transplantation
• Patients must be human immunodeficiency virus (HIV) non-reactive
• Females of childbearing potential must not be pregnant or breastfeeding on admission for conditioning for SCT and a pregnancy test will be required for all females of child-bearing potential
• Patients must have a pre-transplant multi-organ assessment with the following outcome:
• A resting ejection fraction of 50% or greater which increases with exercise as demonstrated by resting/exercise multigated acquisition (MUGA)
• A forced expiratory volume in one second (FEV1) of 60% or greater, a diffusion capacity of 50% or greater, and a oxygen partial pressure (PO2) of 80 mm mercury (Hg) or greater on pulmonary function testing
• A serum creatinine of equal or less than 2.0mg/Dl and a creatinine clearance of 50 mL/min or greater on 24 hour urine collection
• A total bilirubin of less than 2.5 mg/dL, unless these values are due to underlying hematologic malignancy
• An aspartate aminotransferase (AST) less than 2 times the upper limit of normal, unless these values are due to underlying hematologic malignancy
• Be able to tolerate topical application of phenylephrine to the oral mucosa
• All patients must sign a written informed consent

Exclusion Criteria

• Open or unhealed wounds or ulcers in the oral cavity
• Current use or use within past two weeks of an monoamine oxidase inhibitor (MAOI)
• Primary or secondary tumor in the oral cavity
• Known allergy to phenylephrine
• Uncontrolled hypertension (defined as blood pressure in adults > 150/95)

• Patients on anti-hypertensive medications are eligible if blood pressure is controlled
• Enrollment in any other mucositis prevention study from screening up to day 45 post-stem cell transplant
• Patients who are not eligible to receive SCT with cyclophosphamide and total body irradiation (TBI) conditioning because they do not meet transplant criteria are also not eligible for this phenylephrine study

• Patients who have angina and/or congestive heart failure requiring treatment, or who have had a myocardial infarction within the past year
• Patients who have had any complication that makes the risk of death during transplantation from non-malignant causes greater than the risk of relapse
• Patients who have any active infection; if the infection is successfully treated, the patient may be reconsidered for transplantation at a later date
• Patients with diabetes who are not controlled by medical management will be ineligible
• Psychiatric illness requiring psychiatric counseling or medical intervention other than antidepressant medications may make an individual ineligible and will be considered on a case-by-case basis
• Psychosocial assessment by the bone marrow transplant team may identify individuals for whom this form of therapy may be contraindicated; these decisions will be based upon estimated adequacy of patient support systems and prediction of patient's compliance with medications, required diagnostic procedures, and/or follow-up care
• Patients who have an ECOG performance status of greater than 2
• Patients who have decreased pulmonary function due to any disorder as demonstrated by a diffusion capacity of less than 50% of predicted, a FEV1 of less than 60% of predicted, or a PO2 of less than 80mmHg on pulmonary function testing
• Patients who have a resting ejection fraction of less than 50%
• Patients who have renal disease as demonstrated by a serum creatinine clearance of greater than 2.0 mg/dL and/or a creatinine clearance of less than 50 mL/min
• Patients who are pregnant or breast feeding at the time of admission for conditioning
• Any mental or physical condition, in the opinion of the principal investigator (PI) or PI designee, which could interfere with the ability of the subject to understand or adhere to the requirements of the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Wisconsin, Madison

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Margo L. Hoover-Regan

Role: PRINCIPAL_INVESTIGATOR

University of Wisconsin, Madison

Locations

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, United States

Countries

United States

Related Links

https://cancer.wisc.edu/

University of Wisconsin Carbone Cancer Center

Other Identifiers

NCI-2015-00576

Identifier Type: OTHER

Identifier Source: secondary_id

2015-0062

Identifier Type: OTHER

Identifier Source: secondary_id

A536700

Identifier Type: OTHER

Identifier Source: secondary_id

SMPH\PEDIATRICS\PEDIATRICS

Identifier Type: OTHER

Identifier Source: secondary_id

UW14068

Identifier Type: -

Identifier Source: org_study_id